Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 August;55(4) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 August;55(4):353-73

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  BONE METASTASES 2011:NEW ACHIEVEMENTS OF DIAGNOSTIC AND THERAPEUTIC NUCLEAR MEDICINE


The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 August;55(4):353-73

language: English

Pathophysiological premises to radiotracers for bone metastases

Cuccurullo V. 1, Cascini G. L. 2, Rossi A. 1, Tamburrini O. 2, Rotondo A. 3, Mansi L. 1

1 Nuclear Medicine Division, Second University of Naples, Naples, Italy
2 Department of Radiological Sciences, University of Catanzaro, Catanzaro, Italy
3 Department of Radiological Sciences, Second University of Naples, Naples, Italy


PDF  


Aim of our paper is to review the most important radio-compounds that can be successfully used to detect and/or characterize bone metastases. From a didactic point of view, we made a distinction between two main categories , the first allowing to individuate bone’s reaction (osteotropic agents), the second trying to detect metastatic tumor cells (oncotropic agents). A wide description of the most diffuse Tc-99m diphosphonates , including analysis of uptake mechanisms and pharmacokinetics, is followed by a brief report on pathophysiological premises to the clinical use of F-18 fluoride and of specific (radioiodine, radiolabeled somatostatin or cathecolamine analogues) or non specific, as Tc-99m sestamibi, F-18 fluorodeoxhyglucose, F-18 choline, F-18 thymidine) oncotropic agents. At the end, the possibility to use diagnostic radiotracers to act both in recruiting patients with bone metastases undergoing radionuclide therapy and for their dosimetric evaluation is also discussed.

top of page

Publication History

Cite this article as

Corresponding author e-mail

luigi.mansi@unina2.it